deaths (OS)

mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) 1 certainty unassessable-27%
atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1 certainty unassessable+11%